α-Syn H21 Monoclonal Antibody

Phase 1

α-Syn H21 Monoclonal Antibody is one of 14 therapeutic programs targeting Multiple System Atrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple System AtrophyNot yet recruiting

Multiple System AtrophyPhase 1

Not yet recruiting

Competition

Competitive Landscape

20 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Rifadin

Northera

Sudafed

Rilutek

AAzurity Pharmaceuticals

Lu AF95245

1 6

TEV-56286

Teva

Phase 2

2 7

Foralumab

TTiziana Life Sciences LTD

Phase 2

1 8

Bendopa

MMerz North America, Inc.

Preclinical

1 9

ATH434

AAlterity Therapeutics

Phase 2

2 10

Human Dopaminergic Progenitor Cells

IiRegene Therapeutics Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Multiple System Atrophy

NCT07774585

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy

Not yet recruiting·RRuijin Hospital·Phase 1·NCT07774585·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for α-Syn H21 Monoclonal Antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for α-Syn H21 Monoclonal Antibody. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: RRuijin Hospital

α-Syn H21 Monoclonal Antibody

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News